Home » Stocks » DNLI

Denali Therapeutics Inc. (DNLI)

Stock Price: $51.03 USD 0.04 (0.08%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $51.16 +0.13 (0.26%) Jul 30, 5:06 PM
Market Cap 6.18B
Revenue (ttm) 339.98M
Net Income (ttm) 57.86M
Shares Out 120.88M
EPS (ttm) 0.49
PE Ratio 103.72
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $51.03
Previous Close $50.99
Change ($) 0.04
Change (%) 0.08%
Day's Open 50.79
Day's Range 50.75 - 53.04
Day's Volume 563,818
52-Week Range 22.75 - 93.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug.

6 days ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., July 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

1 week ago - GlobeNewsWire

Management to host webinar for analysts and investors on July 25th Management to host webinar for analysts and investors on July 25th

2 weeks ago - GlobeNewsWire

ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.

Other stocks mentioned: ACCD, FHB, FSLY, GH
3 weeks ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

1 month ago - GlobeNewsWire

Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company

1 month ago - Zacks Investment Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

It signals a big push toward curing a neurological disease with a massive market.

Other stocks mentioned: LLY, MRNA, SAVA, SNY
2 months ago - The Motley Fool

Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.

2 months ago - Zacks Investment Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -56.76% and -72.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross ...

2 months ago - GlobeNewsWire

Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug is being developed in collaboration with Biog...

Other stocks mentioned: BIIB
2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross ...

3 months ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

It has been a while for sure, but as the old adage says that every dog has his or her day.

Other stocks mentioned: LSCC, O, YETI, FND
4 months ago - 24/7 Wall Street

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...

Other stocks mentioned: FATE, MRNA, MRTX, NVAX, SGEN, ZLAB
4 months ago - InvestorPlace

The biotech received good news from the FDA concerning one of its pipeline candidates.

4 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros...

4 months ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Other stocks mentioned: ABNB, EDIT, CNP, AGIO, PTR, TREE, VYGR ...
5 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, EVLO, FHTX, KLDO, MCRB, MRNA ...
5 months ago - PRNewsWire

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

5 months ago - GlobeNewsWire

– Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time – – Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time –

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

6 months ago - GlobeNewsWire

2020 is almost over. Maybe it's time to cash in -- and cash out?

Other stocks mentioned: BLNK, MDB, AMPE
7 months ago - The Motley Fool

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: CRSP, MCRB, NK, RCKT
7 months ago - Zacks Investment Research

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, CRSP, MRTX, NVAX, SGEN, ZLAB
7 months ago - InvestorPlace

While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.

Other stocks mentioned: RHHBY, SAVA
8 months ago - The Motley Fool

Denali Therapeutics (DNLI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

9 months ago - GlobeNewsWire

— Webinar scheduled for Thursday, October 15th at 1:00 p.m. Eastern Time —

10 months ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 8.20% and 57.60%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro...

11 months ago - GlobeNewsWire

Denali Therapeutics Inc. (NASDAQ: DNLI) announced early on Thursday that it would be progressing its Parkinson’s treatment into late-stage studies, and investors cheered on this move.

11 months ago - 24/7 Wall Street

Shares of Denali Therapeutics Inc (NASDAQ: DNLI) are racing toward their 52-week high following a clinical pipeline update concerning the company's Parkinson's disease pipeline.

11 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro...

1 year ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, June 09, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the b...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cr...

1 year ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cr...

1 year ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small mol... [Read more...]

Industry
Biotechnology
IPO Date
Dec 8, 2017
CEO
Ryan Watts
Employees
311
Stock Exchange
NASDAQ
Ticker Symbol
DNLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for DNLI stock is "Buy." The 12-month stock price forecast is 79.89, which is an increase of 56.55% from the latest price.

Price Target
$79.89
(56.55% upside)
Analyst Consensus: Buy